TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30940341

Group type: EXPERIMENTAL
Intervention: Vorvida intervention
Number of subjects: 608

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 608
Study: 28472101

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (E2) treatment for 1 week
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (PL) treatment for 1 week
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (E2) treatment
Number of subjects: 35
Study: 25832111

Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 23808527

Group type: EXPERIMENTAL
Intervention: Financial incentive (exit exam)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control (book voucher raffle)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Financial incentive
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control
Number of subjects: 121
Study: 21788837

Group type: EXPERIMENTAL
Intervention: Intense pulsed light treatment (two times per week for 4 weeks using a Harmony Laser)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (no treatment on the contralateral side)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intense pulsed light treatment
Number of subjects: 18
Study: 19519240

Group type: EXPERIMENTAL
Intervention: HIV prevalence
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Other sexually transmitted diseases prevalence
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Reported sexual behavior
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Recent anal intercourse partners
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Unprotected anal intercourse
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Risk predictors
Number of subjects: 156
Study: 17466464

Group type: EXPERIMENTAL
Intervention: Non-syringe paraphernalia-sharing (NSPS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Syringe-mediated drug-splitting (SMDS)
Number of subjects: 0
Study: 14999204

Group type: EXPERIMENTAL
Intervention: Nurse-based educational intervention
Number of subjects: 756

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 756
Study: 11707555

Group type: EXPERIMENTAL
Intervention: Energy-restricted diet of 1200 to 1500 kcal/d (Group A)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Isocaloric diet with nutrient-fortified liquid meal replacements (Group B)
Number of subjects: 100
Study: 9208965

Group type: EXPERIMENTAL
Intervention: Impra graft
Number of subjects: 117

Group type: COMPARATOR
Intervention: Goretex graft
Number of subjects: 117
Study: 7783570

Group type: EXPERIMENTAL
Intervention: ECGs with computer-generated reports
Number of subjects: 40

Group type: COMPARATOR
Intervention: ECGs without reports
Number of subjects: 40
Study: 1982764

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg) alone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg) with piroxicam (40 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Piroxicam (20 mg) with placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Piroxicam (20 mg) with ranitidine (150 mg)
Number of subjects: 18
Study: 356867

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 30650232

Group type: EXPERIMENTAL
Intervention: Overall Compliance in TAIL treatment
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Specific Compliance in TAIL treatment
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Specific Compliance with stress and insomnia components
Number of subjects: 207
Study: 28286047

Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACTZ) 500 mg
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 25039889

Group type: EXPERIMENTAL
Intervention: Aliskiren (150 mg) added to valsartan (80 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Valsartan (80 mg) alone
Number of subjects: 28
Study: 22702891

Group type: EXPERIMENTAL
Intervention: Neurologists' assessment of depression
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Neurologists' assessment of cognitive impairment
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Patients' self-assessment of depression
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Patients' self-assessment of cognitive impairment
Number of subjects: 104
Study: 20350038

Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral (CB) intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group supportive expressive intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CB bibliotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 0
Study: 18538406

Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%/timolol 0.5%
Number of subjects: 523

Group type: COMPARATOR
Intervention: Brinzolamide 1%
Number of subjects: 523

Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 523
Study: 16275826

Group type: EXPERIMENTAL
Intervention: Surrogate consent for biomedical research in minimal risk studies
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Surrogate consent for randomized clinical trials of new medications
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Surrogate consent for more invasive studies
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Decision-making for a loved one
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: General attitude toward biomedical research and scenario-specific risk perception
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Demographic and personal history variables
Number of subjects: 229
Study: 14605518

Group type: EXPERIMENTAL
Intervention: 12-week exercise training intervention
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard pharmacologic therapy
Number of subjects: 23
Study: 10394887

Group type: EXPERIMENTAL
Intervention: ACE inhibitor (group I, 6 patients)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Beta blocker (group II, 6 patients)
Number of subjects: 12
Study: 8523341

Group type: EXPERIMENTAL
Intervention: Prednisolone 20 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Deflazacort 24 mg/day
Number of subjects: 30
Study: 2334306

Group type: EXPERIMENTAL
Intervention: Nonverbal auditory stimuli
Number of subjects: 14

Group type: COMPARATOR
Intervention: Binaural auditory verbal stimuli
Number of subjects: 14

Group type: COMPARATOR
Intervention: Tactile unilateral and bilateral stimuli
Number of subjects: 14

Group type: COMPARATOR
Intervention: No stimulation at all
Number of subjects: 14
Study: 395954

Group type: EXPERIMENTAL
Intervention: Nicergoline
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31186202

Group type: EXPERIMENTAL
Intervention: Standard analgesia plus Battlefield Auricular Acupuncture (BFA)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard analgesia
Number of subjects: 70
Study: 28138865

Group type: EXPERIMENTAL
Intervention: Sensorial training of the posterior thigh in addition to neurodevelopmental treatment
Number of subjects: 26

Group type: COMPARATOR
Intervention: Neurodevelopmental treatment only (control group)
Number of subjects: 26
Study: 26164864

Group type: EXPERIMENTAL
Intervention: Urapidil
Number of subjects: 72

Group type: COMPARATOR
Intervention: Nitroglycerin (NG)
Number of subjects: 72
Study: 23657083

Group type: EXPERIMENTAL
Intervention: DC/PANVAC
Number of subjects: 74

Group type: COMPARATOR
Intervention: PANVAC with GM-CSF
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Vaccinated patients
Number of subjects: 74
Study: 21680669

Group type: EXPERIMENTAL
Intervention: Information on how women may benefit from men's HPV vaccination
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Information on preventing genital warts
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Information on preventing head and neck cancers
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no specific information provided)
Number of subjects: 150
Study: 19628934

Group type: EXPERIMENTAL
Intervention: Aspirin treatment in the UK‐TIA Trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy in the European Carotid Surgery Trial (ECST)
Number of subjects: 0
Study: 17908579

Group type: EXPERIMENTAL
Intervention: Hyperbaric gaseous cryotherapy (2min at 75 bar and -78 degrees C)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ice bag (15min)
Number of subjects: 12
Study: 15529649

Group type: EXPERIMENTAL
Intervention: Glycerin formulation of ototopical 0.3% ciprofloxacin
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional aqueous formulation of ciprofloxacin
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 33
Study: 11211149

Group type: EXPERIMENTAL
Intervention: Interferon‐α (IFN‐α)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Interferon‐α (IFN‐α) with anthracycline‐containing induction chemotherapy
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (no IFN‐α)
Number of subjects: 9
Study: 9012900

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) at a low dose of 10 ppm
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Therapeutic inhalation of nitric oxide (NO)
Number of subjects: 22
Study: 10146734

Group type: EXPERIMENTAL
Intervention: Clear Horizons and two counselor calls
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Clear Horizons alone
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Control guide (Clearing the Air)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Tailored interventions (Clear Horizons)
Number of subjects: 2000
Study: 3580158

Group type: EXPERIMENTAL
Intervention: Cisplatin and fluorouracil as neoadjuvant chemotherapy followed by standard treatment.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard treatment (preoperative irradiation followed by radical excision or irradiation alone).
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Experimental group (adjuvant chemotherapy followed by standard treatment).
Number of subjects: 60
Study: 29650764

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: Baseline PRA
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: TXNDC11 expression
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: Proxy SNP rs1802409
Number of subjects: 758
Study: 27391833

Group type: EXPERIMENTAL
Intervention: Fat grafting (mean volume of 4.8 cc per foot)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 25
Study: 25007905

Group type: EXPERIMENTAL
Intervention: Venotrain ulcertec® (VU) compression stocking
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Venotrain micro® (VM) compression stocking
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no compression)
Number of subjects: 60
Study: 24322122

Group type: EXPERIMENTAL
Intervention: Correction of defocus fluctuations
Number of subjects: 4

Group type: COMPARATOR
Intervention: All aberrations except defocus were corrected
Number of subjects: 4

Group type: COMPARATOR
Intervention: Uncorrected aberrations
Number of subjects: 4
Study: 20467269

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 3071
Study: 18383418

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 315

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study: 16632233

Group type: EXPERIMENTAL
Intervention: 3x daily insulin lispro
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: 3x daily lispro mid mixture (MidMix; 50% lispro, 50% protaminated lispro)
Number of subjects: 159

Group type: COMPARATOR
Intervention: 1x daily insulin glargine
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: 3x daily lispro mid mixture (MidMix)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 159
Study: 14653833

Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 10759875

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8833708

Group type: EXPERIMENTAL
Intervention: Hyperhydration (HH) with fluid intake of 4.6 ± 0.2.day(‐1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Voluntary hydration (VH) with fluid intake of 2.7 ± 0.2.day(‐1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both hydration conditions (HH and VH)
Number of subjects: 8
Study: 1385036

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 674

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 674
Study: 3881633

Group type: EXPERIMENTAL
Intervention: High-frequency lung ventilation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional mechanical lung ventilation
Number of subjects: 0
Study: 30789801

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) 1200 mg/day for 8 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 29509867

Group type: EXPERIMENTAL
Intervention: Opioid medications (immediate-release morphine, oxycodone, or hydrocodone/acetaminophen)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Nonopioid medications (acetaminophen or NSAIDs)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Opioid medications
Number of subjects: 240

Group type: COMPARATOR
Intervention: Nonopioid medications
Number of subjects: 240
Study: 27338193

Group type: EXPERIMENTAL
Intervention: Carboplatin plus paclitaxel doublet chemotherapy
Number of subjects: 451

Group type: COMPARATOR
Intervention: Monotherapy (vinorelbine or gemcitabine)
Number of subjects: 451
Study: 24937018

Group type: EXPERIMENTAL
Intervention: Iyengar yoga (twice weekly)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health and wellness classes (twice weekly)
Number of subjects: 0
Study: 22716999

Group type: EXPERIMENTAL
Intervention: 10 mg escitalopram daily for 7 days
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 19130460

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 17684066

Group type: EXPERIMENTAL
Intervention: Biventricular (BiV) pacing
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Left univentricular (LUV) pacing
Number of subjects: 18
Study: 15248217

Group type: EXPERIMENTAL
Intervention: Intermediate dose of parenteral methotrexate (15 mg/m(2)/week)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Higher dose of parenteral methotrexate (30 mg/m(2)/week)
Number of subjects: 133
Study: 12324294

Group type: EXPERIMENTAL
Intervention: Zinc (20 mg/d for infants, 40 mg/d for older children)
Number of subjects: 1087

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1087
Study: 9852724

Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Elemental Diet (ED)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Polymeric Diet (PD)
Number of subjects: 28
Study: 8207189

Group type: EXPERIMENTAL
Intervention: Maximal sterile barrier precautions (mask, cap, sterile gloves, gown, and large drape)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Control precautions (sterile gloves and small drape only)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Maximal sterile barrier precautions
Number of subjects: 343
Study: 2590267

Group type: EXPERIMENTAL
Intervention: 800 mg theophylline administered at 8 a.m.
Number of subjects: 10

Group type: COMPARATOR
Intervention: 800 mg theophylline administered at 8 p.m.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 800 mg theophylline administered at 8 a.m. and 8 p.m.
Number of subjects: 10
Study: 31793032

Group type: EXPERIMENTAL
Intervention: Personalized extracorporeal biofeedback device for pelvic floor muscle training (PFMT)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (standard care without biofeedback device)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Personalized extracorporeal biofeedback device for PFMT
Number of subjects: 84
Study: 26506570

Group type: EXPERIMENTAL
Intervention: JB01-BD (anti-HPV biological dressing)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Non-treatment group
Number of subjects: 77
Study: 26279130

Group type: EXPERIMENTAL
Intervention: Switching to bupropion-SR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Augmenting with bupropion-SR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Augmenting with aripiprazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (current antidepressant)
Number of subjects: 0
Study: 23503737

Group type: EXPERIMENTAL
Intervention: Regent Suit
Number of subjects: 60
Study: 20159529

Group type: EXPERIMENTAL
Intervention: Rectally administered indomethacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19010927

Group type: EXPERIMENTAL
Intervention: Fenretinide (200 mg/daily)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Low-dose tamoxifen (5 mg/daily)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Combination of fenretinide and tamoxifen
Number of subjects: 235

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study: 16161398

Group type: EXPERIMENTAL
Intervention: 5th generation bonding system (Optibond Solo)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 6th generation bonding system (Prompt‐L‐Pop)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 7th generation bonding system (iBond)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no dentinal bonding system)
Number of subjects: 80
Study: 12959471

Group type: EXPERIMENTAL
Intervention: Camperdown Program (prolonged-speech treatment model)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Camperdown Program
Number of subjects: 16
Study: 10837289

Group type: EXPERIMENTAL
Intervention: Iron supplementation (20 mg Fe)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study: 8895944

Group type: EXPERIMENTAL
Intervention: Single intravenous administration of 25 mg doxepin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Three-week open oral treatment with 25 mg doxepin daily
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 1671471

Group type: EXPERIMENTAL
Intervention: Pump-driven haemofiltration (PDHF)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control (CAVH)
Number of subjects: 116
Study: 6554617

Group type: EXPERIMENTAL
Intervention: Procedure information
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Procedure and sensation information
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Procedure and sensation information plus information on selected coping strategies
Number of subjects: 111
Study: 30678655

Group type: EXPERIMENTAL
Intervention: Trendelenburg position (-15°) as soon as regurgitation was noticed
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Sellick position
Number of subjects: 84

Group type: COMPARATOR
Intervention: Sniffing position
Number of subjects: 84
Study: 28988643

Group type: EXPERIMENTAL
Intervention: Novel fitting algorithm
Number of subjects: 50

Group type: COMPARATOR
Intervention: Traditional method
Number of subjects: 50
Study: 26093810

Group type: EXPERIMENTAL
Intervention: Home exercises (one supervised exercise treatment followed by exercises at home for 6 weeks)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Supervised exercises (up to 10 supervised exercise treatments in addition to home exercises for 6 weeks)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Clinical tests of shoulder impingement (part of secondary outcomes)
Number of subjects: 46
Study: 23948997

Group type: COMPARATOR
Intervention: Standard daily S‐1 administration (80‐120 mg/day depending on BSA; days 1‐28 every 6 weeks for 1 year)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Alternate-day S‐1 administration (80‐120 mg/day depending on BSA; alternate days for 15 months)
Number of subjects: 73
Study: 21940136

Group type: EXPERIMENTAL
Intervention: Motivational interviewing plus mindfulness meditation (MI-MM)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 34
Study: 19568216

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) training
Number of subjects: 15

Group type: COMPARATOR
Intervention: Usual practice (Control)
Number of subjects: 15
Study: 16639521

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study: 12819313

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (individualized counseling to reduce weight, total and saturated fat intake, and increase fiber intake and physical activity)
Number of subjects: 522

Group type: COMPARATOR
Intervention: Control group (no lifestyle intervention)
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 522
Study: 11016525

Group type: EXPERIMENTAL
Intervention: Affective psychosis diagnosis
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: Non-affective psychosis diagnosis
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: DSM-III-R categories
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: ICD-10 categories
Number of subjects: 708
Study: 8638999

Group type: EXPERIMENTAL
Intervention: Nasal mupirocin ointment (5-day course every month for 1 year)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Nasal mupirocin ointment
Number of subjects: 34
Study: 1386857

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 42 micrograms
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 21 micrograms
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 6468768

Group type: EXPERIMENTAL
Intervention: Atropine (5 micrograms X kg‐1 X h‐1)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Atropine (15 micrograms X kg‐1 X h‐1)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Cholecystokinin (CCK)
Number of subjects: 7
Study: 31483689

Group type: EXPERIMENTAL
Intervention: Somatic yoga and meditation (weekly for 8 weeks, with home program)
Number of subjects: 8
Study: 30253712

Group type: EXPERIMENTAL
Intervention: Automated blood pressure self-measurement (BPSM) using a self-measurement station on one arm.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Office blood pressure measurement (OBPM) performed by clinical staff on both arms.
Number of subjects: 80